Ropes & Gray Advised Spyre Therapeutics In $316 Million Public Offering

Ropes & Gray Advised Spyre Therapeutics in $316 Million Public Offering

Ropes & Gray represented Spyre Therapeutics in a $316 million public offering of 17,094,594 shares of its common stock, including the full exercise of the underwriters’ option to purchase up to 2,229,729 additional shares at a public offering price per share of $18.50. The offering priced on October 13, 2025, and closed on October 15, 2025.

Spyre is a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of inflammatory bowel disease and other immune-mediated diseases.

The Ropes & Gray team was led by Tom Danielski (Partner), and Emily Weiss-Cook (Associate).

If you have a news or deal publication or would like to collaborate on content, columns, or article publications, connect with the Legal Era News Network Team and email us at info@legalera.in or call us on +91 8879634922.